

# Clinical Update



**U.S. FOOD & DRUG  
ADMINISTRATION**

[A to Z Index](#) | [Follow FDA](#) | [En Español](#)

Search FDA



[Home](#) [Food](#) [Drugs](#) [Medical Devices](#) [Radiation-Emitting Products](#) [Vaccines, Blood & Biologics](#) [Animal & Veterinary](#) [Cosmetics](#) [Tobacco Products](#)

## News & Events

[Home](#) > [News & Events](#) > [Newsroom](#) > [Press Announcements](#)

### FDA News Release

## FDA approves new eczema drug Dupixent

[f SHARE](#) [t TWEET](#) [in LINKEDIN](#) [p PIN IT](#) [e EMAIL](#) [p PRINT](#)

**For Immediate  
Release**

March 28, 2017

**Release**

[Español](#)

The U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable. Dupixent can be used with or without topical corticosteroids.

### Inquiries

#### Media

[✉ Sarah Peddicord](#)  
[☎ 301-796-2805](#)

[✉ Andrea Fischer](#)  
[☎ 301-796-0393](#)

#### Consumers

[☎ 888-INFO-FDA](#)

### Related Information

- [FDA Approved Drugs: Questions and Answers](#)

# Clinical Update: Dupilumab

Beck et al. *N Engl J Med*. 2014 Jul 10;371(2):130-9